American Society of Hematology

Figure 3

$Figure 3. Change in the sum of the product of diameters, measured by computed tomography. (A) Efficacy population (n = 26). (B) Patients refractory to brentuximab vedotin as the most recent treatment prior to AFM13 (n = 7). (C) Patients treated with AFM doses ≥1.5 mg/kg body weight (n = 13).$

Change in the sum of the product of diameters, measured by computed tomography. (A) Efficacy population (n = 26). (B) Patients refractory to brentuximab vedotin as the most recent treatment prior to AFM13 (n = 7). (C) Patients treated with AFM doses ≥1.5 mg/kg body weight (n = 13).

This Feature Is Available To Subscribers Only